134 related articles for article (PubMed ID: 37966980)
21. COVID-19 Infection in Chronic Myeloid Leukemia Patients Receiving Tyrosine Kinase Inhibitor in Makassar, Indonesia: A Six-Case Report and Literature Review.
Harjianti T; Benyamin F; Minhajat R; Saleh S; Bayu D; Pababbari W
Acta Med Indones; 2023 Jul; 55(3):332-338. PubMed ID: 37915153
[TBL] [Abstract][Full Text] [Related]
22. SARS-CoV-2 Omicron BA.5.2-infection and COVID-19 in persons with chronic myeloid leukaemia.
Cheng F; Xiang H; Gale RP; Chen S; Qu J; Guo H; Li Q; Zhang Y; Li W
J Cancer Res Clin Oncol; 2023 Oct; 149(13):11025-11030. PubMed ID: 37337067
[TBL] [Abstract][Full Text] [Related]
23. Clinical characteristics and risk factors associated with COVID-19 severity in patients with haematological malignancies in Italy: a retrospective, multicentre, cohort study.
Passamonti F; Cattaneo C; Arcaini L; Bruna R; Cavo M; Merli F; Angelucci E; Krampera M; Cairoli R; Della Porta MG; Fracchiolla N; Ladetto M; Gambacorti Passerini C; Salvini M; Marchetti M; Lemoli R; Molteni A; Busca A; Cuneo A; Romano A; Giuliani N; Galimberti S; Corso A; Morotti A; Falini B; Billio A; Gherlinzoni F; Visani G; Tisi MC; Tafuri A; Tosi P; Lanza F; Massaia M; Turrini M; Ferrara F; Gurrieri C; Vallisa D; Martelli M; Derenzini E; Guarini A; Conconi A; Cuccaro A; Cudillo L; Russo D; Ciambelli F; Scattolin AM; Luppi M; Selleri C; Ortu La Barbera E; Ferrandina C; Di Renzo N; Olivieri A; Bocchia M; Gentile M; Marchesi F; Musto P; Federici AB; Candoni A; Venditti A; Fava C; Pinto A; Galieni P; Rigacci L; Armiento D; Pane F; Oberti M; Zappasodi P; Visco C; Franchi M; Grossi PA; Bertù L; Corrao G; Pagano L; Corradini P;
Lancet Haematol; 2020 Oct; 7(10):e737-e745. PubMed ID: 32798473
[TBL] [Abstract][Full Text] [Related]
24. Outcome of COVID-19 in patients with chronic myeloid leukemia receiving tyrosine kinase inhibitors.
Cakir B
J Oncol Pharm Pract; 2020 Dec; 26(8):2068-2069. PubMed ID: 33081582
[No Abstract] [Full Text] [Related]
25. Chronic myeloid leukemia among patients with a history of prior malignancies: A tale of dual survivorship.
Koller PB; Kantarjian HM; Nogueras-Gonzalez GM; Jabbour E; Verstovsek S; Borthakur G; Estrov Z; Wierda WG; Garcia-Manero G; Ferrajoli A; Ravandi F; O'Brien SM; Cortes JE
Cancer; 2017 Feb; 123(4):609-616. PubMed ID: 27763690
[TBL] [Abstract][Full Text] [Related]
26. Using healthcare claims data to analyze the prevalence of BCR-ABL-positive chronic myeloid leukemia in France: A nationwide population-based study.
Foulon S; Cony-Makhoul P; Guerci-Bresler A; Delord M; Solary E; Monnereau A; Bonastre J; Tubert-Bitter P
Cancer Med; 2019 Jun; 8(6):3296-3304. PubMed ID: 31038849
[TBL] [Abstract][Full Text] [Related]
27. The rising prevalence of chronic myeloid leukemia in France.
Delord M; Foulon S; Cayuela JM; Rousselot P; Bonastre J
Leuk Res; 2018 Jun; 69():94-99. PubMed ID: 29734071
[TBL] [Abstract][Full Text] [Related]
28. Patients with chronic myeloid leukemia and coronavirus disease 2019 in the Omicron era.
Qi F; Bao M; Gao H; Zhang X; Zhao S; Wang C; Li W; Jiang Q
Ann Hematol; 2023 Oct; 102(10):2707-2716. PubMed ID: 37578540
[TBL] [Abstract][Full Text] [Related]
29. Haematological malignancies in developing countries: is CML the commonest childhood leukaemia?
Wechalekar AD; Parande CM
Leukemia; 2007 Oct; 21(10):2194; author reply 2195. PubMed ID: 17673905
[No Abstract] [Full Text] [Related]
30. Estimations of the increasing prevalence and plateau prevalence of chronic myeloid leukemia in the era of tyrosine kinase inhibitor therapy.
Huang X; Cortes J; Kantarjian H
Cancer; 2012 Jun; 118(12):3123-7. PubMed ID: 22294282
[TBL] [Abstract][Full Text] [Related]
31. COVID-19 infection in patients with haematological malignancies: A single-centre survey in the latest Omicron wave in China.
Zhu X; Jiang Q; Lu J; Sun Y; Zhao X; Yang S; Tang F; Yu W; Zhao T; Liu X; Jia J; Duan W; Hu L; Wang J; Liu Y; Peng N; Dou X; Ma R; Fu Q; Wang H; Liu K; Huang X; Jiang H
Br J Haematol; 2023 Jul; 202(1):31-39. PubMed ID: 37092433
[TBL] [Abstract][Full Text] [Related]
32. Passive pre-exposure immunization by tixagevimab/cilgavimab in patients with hematological malignancy and COVID-19: matched-paired analysis in the EPICOVIDEHA registry.
Marchesi F; Salmanton-García J; Buquicchio C; Itri F; Besson C; Dávila-Valls J; Martín-Pérez S; Fianchi L; Rahimli L; Tarantini G; Grifoni FI; Sciume M; Labrador J; Cordoba R; López-García A; Fracchiolla NS; Farina F; Ammatuna E; Cingolani A; García-Bordallo D; Gräfe SK; Bilgin YM; Dargenio M; González-López TJ; Guidetti A; Lahmer T; Lavilla-Rubira E; Méndez GA; Prezioso L; Schönlein M; Van Doesum J; Wolf D; Hersby DS; Magyari F; Van Praet J; Petzer V; Tascini C; Falces-Romero I; Glenthøj A; Cornely OA; Pagano L
J Hematol Oncol; 2023 Apr; 16(1):32. PubMed ID: 37005697
[TBL] [Abstract][Full Text] [Related]
33. Dasatinib: a review of its use in the treatment of chronic myeloid leukaemia and Philadelphia chromosome-positive acute lymphoblastic leukaemia.
McCormack PL; Keam SJ
Drugs; 2011 Sep; 71(13):1771-95. PubMed ID: 21902298
[TBL] [Abstract][Full Text] [Related]
34. [Effect of gemcitabine on granulocyte colony-stimulating factor receptor and bcr/abl mRNA in patients with chronic myeloid leukemia].
Liu D; Wang F; Sun L; Liu LX; Liu YF; Ling Z; Han XF
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2010 Oct; 18(5):1168-71. PubMed ID: 21129254
[TBL] [Abstract][Full Text] [Related]
35. Generic imatinib in the treatment of chronic myeloid leukemia: two years' experience in Latvia.
Lejniece S; Udre I; Rivkina A
Exp Oncol; 2017 Jul; 39(2):151-154. PubMed ID: 29483494
[TBL] [Abstract][Full Text] [Related]
36. Treatment patterns and prognostic indicators of response to therapy among patients with chronic myeloid leukemia in Australia, Canada, and South Korea.
Whiteley J; Iyer S; Candrilli SD; Kaye JA
Curr Med Res Opin; 2015 Feb; 31(2):299-314. PubMed ID: 25427232
[TBL] [Abstract][Full Text] [Related]
37. Decoding the historical tale: COVID-19 impact on haematological malignancy patients-EPICOVIDEHA insights from 2020 to 2022.
Salmanton-García J; Marchesi F; Farina F; Weinbergerová B; Itri F; Dávila-Valls J; Martín-Pérez S; Glenthøj A; Hersby DS; Gomes da Silva M; Nunes Rodrigues R; López-García A; Córdoba R; Bilgin YM; Falces-Romero I; El-Ashwah S; Emarah Z; Besson C; Kohn M; Van Doesum J; Ammatuna E; Marchetti M; Labrador J; Zambrotta GPM; Verga L; Jaksic O; Nucci M; Piukovics K; Cabirta-Touzón A; Jiménez M; Arellano E; Espigado I; Blennow O; Nordlander A; Meers S; van Praet J; Aiello TF; Garcia-Vidal C; Fracchiolla N; Sciumè M; Seval GC; Žák P; Buquicchio C; Tascini C; Gräfe SK; Schönlein M; Adžić-Vukičević T; Bonuomo V; Cattaneo C; Nizamuddin S; Čerňan M; Plantefeve G; Prin R; Szotkovski T; Collins GP; Dargenio M; Petzer V; Wolf D; Čolović N; Prezioso L; Valković T; Passamonti F; Méndez GA; Sili U; Vena A; Bavastro M; Limongelli A; Duarte RF; Ledoux MP; Cvetanoski M; Stojanoski Z; Machado M; Batinić J; Magliano G; Biernat MM; Pantić N; Poulsen CB; Cuccaro A; Del Principe MI; Kulasekararaj A; Ormazabal-Vélez I; Busca A; Demirkan F; Ijaz M; Klimko N; Stoma I; Khostelidi S; Fernández N; Omrani AS; Bergantim R; De Jonge N; Fouquet G; Navrátil M; Abu-Zeinah G; Samarkos M; Maertens J; De Ramón C; Guidetti A; Magyari F; González-López TJ; Lahmer T; Finizio O; Ali N; Pinczés LI; Lavilla-Rubira E; Romano A; Merelli M; Delia M; Calbacho M; Meletiadis J; Antić D; Hernández-Rivas JÁ; Marques de Almeida J; Al-Khabori M; Hoenigl M; Tisi MC; Khanna N; Barać A; Eisa N; Di Blasi R; Liévin R; Miranda-Castillo C; Bahr NC; Lamure S; Papa MV; Yahya A; Aujayeb A; Novák J; Erben N; Fernández-Galán M; Ribera-Santa Susana JM; Rinaldi I; Fazzi R; Piedimonte M; Duléry R; Gonzaga Y; Soto-Silva A; Sapienza G; Serris A; Drgoňa Ľ; Groh A; Serrano L; Gavriilaki E; Tragiannidis A; Prattes J; Coppola N; Otašević V; Mladenović M; Mitrović M; Mišković B; Jindra P; Zompi S; Sacchi MV; Krekeler C; Infante MS; García-Bordallo D; Çolak GM; Mayer J; Nygaard M; Hanáková M; Ráčil Z; Bonanni M; Koehler P; Rahimli L; Cornely OA; Pagano L;
EClinicalMedicine; 2024 May; 71():102553. PubMed ID: 38533127
[TBL] [Abstract][Full Text] [Related]
38. BCR-ABL Transcript Level as Compared to LDH and Uric Acid Among Chronic Myeloid Leukemic Patients.
Hailemariam TS; Mehdi M; Kinde S; Seifu D; Edao A
Recent Pat Anticancer Drug Discov; 2021; 16(3):445-455. PubMed ID: 33618649
[TBL] [Abstract][Full Text] [Related]
39. Targeting Hedgehog signaling pathway and autophagy overcomes drug resistance of BCR-ABL-positive chronic myeloid leukemia.
Zeng X; Zhao H; Li Y; Fan J; Sun Y; Wang S; Wang Z; Song P; Ju D
Autophagy; 2015; 11(2):355-72. PubMed ID: 25701353
[TBL] [Abstract][Full Text] [Related]
40. Dasatinib: from treatment of imatinib-resistant or -intolerant patients with chronic myeloid leukemia to treatment of patients with newly diagnosed chronic phase chronic myeloid leukemia.
Abbott BL
Clin Ther; 2012 Feb; 34(2):272-81. PubMed ID: 22285209
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
